Business Units: CSL Behring and Sequirius revenue up 17%, EBIT up 30% (Outperformance in Immunoglobulins and Specialty Products (Berinert). Seqirus (Flu) sales and EBIT were better than anticipated.) | Net operating cash flow down 5.8% to US$664.2m | Outlook: CSL Group’s net profit after tax (NPAT) is expected to grow in the range of approximately 18 to 20% at constant currency. (Increased FX headwinds to -US$50m (from –US$35m). “Earnings per share (EPS) are again expected to exceed profit growth.”


Please sign in to comment on this wire.